Physician profile
Mamta Gupta
NPI 1003007022
$7,801.78
in general payments reported to CMS, 2019-2025
25 companies · $2,744 in 2025
The $2,744 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $256 · 2021: $586 · 2022: $1,111 · 2023: $987 · 2024: $1,147 · 2025: $2,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,769.84 | 2025 | Rapiblyk |
| Pfizer INC. | $657.16 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $616.35 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $589.24 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.45 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $375.05 | 2019-2023 | Lokelma |
| E.R. Squibb & Sons, L.L.C. | $359.30 | 2019-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $308.59 | 2019-2024 | Dificid, Verquvo, Zerbaxa |
| Shionogi INC | $303.62 | 2022-2025 | Fetroja |
| Abbvie INC. | $300.46 | 2021-2025 | |
| Csl Behring | $280.38 | 2019-2025 | Kcentra |
| Vifor Pharma, INC. | $262.13 | 2022-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $254.09 | 2022-2025 | Ultomiris, Soliris |
| Astellas Pharma US INC | $253.59 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $220.54 | 2023-2025 | Rebyota |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $200.19 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $161.66 | 2025 | Vowst |
| Vertex Pharmaceuticals Incorporated | $105.52 | 2025 | |
| Ge Healthcare | $102.34 | 2024 | |
| Insmed, INC. | $78.79 | 2023 | Arikayce |
| Paratek Pharmaceuticals, INC. | $76.13 | 2019-2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $48.09 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $39.87 | 2019 | |
| Novo Nordisk INC | $22.47 | 2019 | |
| Mylan Specialty L.P. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamta Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.